

1 **Welcome!**

# Eric Snijder

*Professor of Molecular Virology*

*Coordinator SCORE project*




Leiden University Medical Center  
Center for Infectious Diseases



*SCORE received funding from the EU's Horizon  
2020 research and innovation programme  
under grant agreement 101003627*

# 1980's

2



# 2003 and 2020

3

World Health Organization

Search  OK

Location: [WHO](#) > [WHO sites](#) > [Media centre](#) > [Press releases](#) > [Press Releases 2003](#)

[Home](#)  
[Countries](#)  
[Health topics](#)  
[Publications](#)  
[Research tools](#)  
[WHO sites](#)  
[Media centre](#)  
[Press releases](#)

[printable version](#)

## WHO issues a global alert about cases of atypical pneumonia

Business May Spread To Hospital Staff

WHO has been actively working to confirm reports of Hong Kong Special Administrative Region

Cases Of Severe Respiratory Infection  
12 March 2003 | GENETIC  
outbreaks of a severe  
(SAR), China, and Gu

**ISID ProMED**

Published Date: 2019-12-31 00:59:00 CET  
Subject: PRO/AH/EDR> Undiagnosed pneumonia - China (HU): RFI  
Archive Number: 20191230.6864153

UNDIAGNOSED PNEUMONIA - CHINA (HUBEI): REQUEST FOR INFORMATION  
\*\*\*\*\*

A ProMED-mail post  
<http://www.promedmail.org>  
ProMED-mail is a program of the  
International Society for Infectious Diseases  
<http://www.isid.org>


Wuhan unexplained pneumonia has been isolated test results will be announced [as soon as available]



# SILVER (2010-2015)

5

- Flaviviruses
- Picornaviruses
- Coronaviruses
- Alphaviruses
- Noroviruses
- Paramyxoviruses
- Rhabdoviruses
- Bunyaviruses
- Arenaviruses



JUNE 2015

## ANTIVIRAL DRUGS: A VITAL COMPONENT OF A EUROPEAN FIRST RESPONSE TO EMERGING RNA VIRUS INFECTIONS

JOHAN NEYTS<sup>1</sup>, PATRICK CHALTIN<sup>2</sup>, ERIC J. SNIJDER<sup>3</sup> & BRUNO CANARD<sup>4</sup>

<sup>1</sup> Rega Institute for Medical Research, University of Leuven, Belgium ([www.antivirals.be](http://www.antivirals.be))

<sup>2</sup> Centre for Drug Design & Discovery, Leuven, Belgium ([www.cd3.eu](http://www.cd3.eu))

<sup>3</sup> Leiden University Medical Center, the Netherlands

<sup>4</sup> University Aix-Marseille, France

**EBOLA WAS A “WAKE UP CALL”! THE WORLD’S FUNDING BODIES HAVE A MORAL RESPONSIBILITY TO SUPPORT ANTIVIRAL DRUG DEVELOPMENT TO PROTECT AGAINST LETHAL EMERGING VIRUSES.**

The recent humanitarian disaster caused by Ebola virus has alerted governments to the reality of highly pathogenic emerging viruses that can leave trails of morbidity and mortality in their wake. They must now recognise the need to promote the development of effective control and treatment strategies to protect humans and animals from such catastrophes that will inevitably continue to arise in the future. Whilst vaccines play a vital role in immunising humans and animals against virus infection, they are not available to treat all known virus disease. Moreover they cannot treat those already infected. In contrast antiviral drugs against HIV, hepatitis, influenza and herpesviruses are saving the lives of millions of humans every day of the year. Importantly, there is virtually no limit to the theoretical number of antiviral drugs that could be discovered or designed. The technologies exist, consortia of expert academic scientists are ready and willing to discover new inhibitors and pharmaceutical companies will welcome the opportunity to develop and market new products. Governments and funding bodies must act quickly to accelerate the development of safe, effective broad-spectrum antiviral therapeutic agents, which will enable health authorities to generate a state of preparedness.



# 2020

7



EN English

Search


[Home](#) > [News](#) > [Coronavirus: EU mobilises €10 million for research](#)

NEWS | 31 January 2020 | Brussels, Belgium | Research and Innovation

## Coronavirus: EU mobilises €10 million for research

The European Commission is boosting urgently needed research into coronavirus with €10 million from its research and innovation programme, Horizon 2020.

**SCORE**  
SWIFT CORONAVIRUS THERAPEUTICS RESPONSE



**C A R E**  
CORONA ACCELERATED R&D IN EUROPE

2022

8



EUROPEAN COMMISSION  
DIRECTORATE-GENERAL FOR RESEARCH AND INNOVATION  
Directorate D – People  
D.1 – Combatting Diseases

EUROPEAN COMMISSION  
EUROPEAN HEALTH EMERGENCY PREPAREDNESS AND RESPONSE AUTHORITY  
2 Intelligence Gathering, Analysis and Innovation

**BROAD-SPECTRUM ANTI-VIRAL THERAPEUTICS:  
A KEY TOOL FOR PANDEMIC PREPAREDNESS**

22-23 November 2022  
Comet Louise, Place Stéphanie 20, 1050 Brussels



2022

9



accessmedicinefoundation.org/resource/some-companies-engaging-in-r-and-d-for-emerging-infectious-diseases-but-pipeline-mainly-empty

access to  
medicine  
FOUNDATION

KEY FINDING 1: R&D PRIORITIES

Some companies engaging in  
R&D for emerging infectious  
diseases, but pipeline mainly  
empty

DATE  
15 November 2022